Christopher Koh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christopher Koh as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05953545 · Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta HepatitisNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · withdrawn · Chronic Hepatitis Delta · principal investigator
- Ph2NCT03600714 · Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda InterferonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · completed · Liver Disease, Hepatitis D · principal investigator
- Ph1/Ph2NCT02118012 · Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis CNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · completed · Chronic Hepatitis C · principal investigator
- N/ANCT00001223 · Diagnosis and Treatment of Patients With Cystic FibrosisNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · terminated · Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Management and Treatment of Chronic Delta Hepatitis Infection and other Liver DiseasesZIADK075150 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · fiscal years 2019 to 2025 · $312,078 awarded in 2025Same name and institution; not confirmed by an ID
- Multidisciplinary Collaborative Clinical Research, Protocol Navigation, Monitoring Compliance, and Other Clinical Services in NIDDK Program Area DiseasesZIDDK070013 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · fiscal years 2024 to 2025 · $4,271,486 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:35 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.Lancet Infect Dis · 2015210 citationsRCR 6.9
- Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.Hepatology · 2018120 citationsRCR 4.6
- Lithium and chlorpromazine: a controlled crossover study of hyperactive severely disturbed young children.J Autism Child Schizophr · 197295 citationsRCR 6.3
- Ribavirin improves early responses to peginterferon through improved interferon signaling.Gastroenterology · 201094 citationsRCR 2.4
- Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children.J Autism Child Schizophr · 197291 citationsRCR 4.4
- Long-term therapy of chronic delta hepatitis with peginterferon alfa.Aliment Pharmacol Ther · 201490 citationsRCR 2.9
- A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.Hepatology · 202261 citationsRCR 4.8
- Classification of lower extremity movement patterns based on visual assessment: reliability and correlation with 2-dimensional video analysis.J Athl Train · 201460 citationsRCR 3.7
- Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.Clin Endocrinol (Oxf) · 199247 citationsRCR 1.9
- 46 citationsRCR 1.3